Clear, Clinically Validated Communication: Transforming Patient Care

The First 60 Minutes after Diagnosis Often Dictate the Next Six Months of a Patient’s Care.

Maya felt the room tilt when the rheumatologist finally named it, systemic lupus erythematosus. Stunned, she kept nodding, promising she got it, even as the explanations dissolved into static. She clutched the bulky discharge packet, telling herself that at home, away from the rising panic, she’d re-read every word and the whole conversation would click. Yet on the bus ride back, terms such as anti-dsDNA titers, steroid-sparing immunosuppressants, and complement C3/C4 levels stared back like a foreign language. The very document meant to guide her next steps now magnified her confusion, setting the stage for missed doses, needless flare-ups, and preventable ER visits. Without clear, accessible communication, many patients like Maya struggle to follow their treatment plans, leading to avoidable hospital visits, complications, and poorer health outcomes. This affects anyone, from those managing diabetes or heart disease to patients facing acute conditions or preventive screenings.

The Persistent Challenge of Health Literacy

Despite advances in medical science and digital health technologies, nearly 90% of U.S. adults struggle to comprehend the information their healthcare providers share. Digital portals have multiplied, and Telehealth is now mainstream, yet comprehension has not improved. Most systems still hand patients the same dense PDF summary and hope they decode it at home. Worldwide, this problem spans age groups and socioeconomic backgrounds, but is most pronounced among chronic illness patients, seniors, and non‑native speakers. Misinterpreted instructions can cause medication errors, reduced adherence to treatment, increased hospital visits, and higher care costs.

Technology Is Not the Whole Prescription

Digital health is advancing rapidly. By 2025, 80% of U.S. physicians will rely on Telehealth, and hospitals are heavily investing in connected platforms. These tools accelerate information sharing and broaden access, but they address only part of patient care. Comprehensive care includes medications, follow-up appointments, medical devices, treatment protocols, and direct interactions with clinicians. Unless patients understand why each medication is prescribed, how to operate a device, and what their next steps are, even the most sophisticated technologies cannot deliver full benefit. Unlocking the promise of modern healthcare requires clear, personalized explanations in plain language at every touchpoint, from the clinic to the patient’s home.

Establishing a New Standard Beyond AI: Clinically Validated Communication

At Patiently, we recognize that effective patient communication is foundational to positive health outcomes. Our approach is rooted in the principle that every piece of health information delivered to patients should be clinically validated and presented with clarity. Leveraging advanced natural language processing and a rigorously maintained medical knowledge base, we translate complex clinical language into explanations that are both precise and understandable. Unlike solutions that rely on black box algorithms or probabilistic text generation, each Patiently explanation is fully traceable to peer-reviewed research and aligned with current medical guidelines. This evidence-based approach deepens patient understanding and builds confidence among clinicians, payers, and health systems.

Driving Patient Engagement and Healthcare Efficiency

Having set a new benchmark for communication, Patiently next demonstrates a measurable impact on engagement and efficiency. Clear, trustworthy explanations increase patients’ confidence and encourage them to take an active role in their care. Studies show that improving health literacy reduces readmission rates by up to 20% and increases medication adherence by 15%. By making complex information accessible, Patiently delivers better clinical metrics, lowers costs, and streamlines workflows for providers.

Looking Ahead: A Future of Truly Patient-Centered Care

As healthcare evolves, demand for personalized, clinically sound communication will intensify. Patiently is committed to leading this transformation, ensuring every individual has access to the clear information they need to make informed decisions. Patiently is expanding multilingual support, integrating seamlessly with electronic health records, and scaling our clinical processes. Together with our partners, we envision a future where no patient ever feels lost in translation. But we do more than clarify information. We foster earlier engagement with patients, improve screening processes and communication from the very first interaction with the healthcare system, and support more efficient and optimized workflows for healthcare providers.

,

About the author

Karin Hason-Novoselsky
Co-Founder & CTO, Patiently

A medical engineer who grew to learn more about how Patiently can empower your patients and clinical teams, visit patiently-app.com. Join us in setting a new benchmark for health communication and patient engagement.

LinkedinProfile
Go back to the Magazine

Subscribe Now to the Bio-Startup Standard

Notify me for the next issue!

    Nature’s Blueprint: How 3D Protein Modeling is Powering the Next Wave of Human – like Nutraceuticals

    Finding Human Proteins in Nature

    The next generation of nutraceuticals is built on a simple but profound insight: nature already holds the key to bifunctionality, with naturally occurring proteins with the potential to affect real change in the human body. The challenge is to find them. At Maolac, our proprietary AI platform combines massive data mining with deep 3D structural modeling to do exactly that.

    Beyond Sequence: The 3D Advantage

    Sequence similarity is not enough. Proteins with similar amino acid strings can fold into very different shapes. What really defines functionality is the 3D structure. Using state-of-the-art tools such as AlphaFold 3, our platform predicts protein structures with near-laboratory accuracy, then aligns them to human proteins. We use RMSD and domain-level comparisons to ensure structural congruence – often reaching 95% structural biosimilarity. This level of matching is what allows proteins sourced from natural sources to behave as if they were made by the human body.

    Human Milk as Nature’s Gold Standard

    Human breast milk is the blueprint for our search. It has been shaped over millions of years to provide optimal support for immunity, gut integrity, and healthy growth. Our AI scouts for proteins in natural sources – colostrum, plants, other biological structures – that have a high 3D and functional similarity to human milk proteins. This bio-inspired approach allows us to transfer the gold standard of early-life nutrition to adult health.

    From Structure to Function: Indication-Specific Protein Selection

    Once structurally similar proteins are identified, we filter them by function: gut barrier repair, anti-inflammatory activity, immune modulation, or muscle recovery. AlphaFold 3’s ability to model multi-molecule complexes helps us predict not only structure but interactions – how these proteins will bind, trigger, or regulate biological pathways.

    This precision has already led to three commercial formulations: – Super Colostrum™ – for vitality and immune resilience – MaolactinGI™ – supports gut health and barrier function – MaolactinFMR™ – accelerates muscle recovery and reduces inflammation.

    Clinical Proof and Market Validation

    Science doesn’t stop at prediction. Our AI-designed ingredients undergo rigorous testing, including randomized clinical trials. Results show measurable benefits in gut health, muscle recovery, and immune resilience. These proven results have driven successful partnerships in the U.S., where our ingredients are already integrated into consumer brands.

    Why It Matters

    This combination of natural sourcing, 3D biosimilarity, and clinical validation is redefining what nutraceuticals can be. Instead of synthetic guesswork, we now have: – Proteins with 95%+ similarity to human proteins – Lower dosages and higher efficacy – Products that have been clinically tested and are already in market

    For the future of functional health products, structure truly matters.

    About the author

    Yuval Appelbaum
    Chief Technology Officer at Maolac

    Yuval Appelbaum is the CTO of MAOLAC, with a B.Sc. in Biotechnology Engineering from Ben-Gurion University of the Negev. She is a co-inventor on several patents and was central to developing and scaling up the company's colostrum and plant-based products. Her expertise includes protein extraction technologies, managing the company's analytical lab, and ensuring compliance with quality standards like ISO and GMP.

    LinkedinProfile
    Go back to the Magazine

    Subscribe Now to the Bio-Startup Standard

    Notify me for the next issue!

      Contact Us
      Contact us






        Skip to content